It's still very early, but this system has the potential to become the standard way that radiation therapy treatments are
done in lung cancer patients,» Vinogradskiy says.
Not exact matches
Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates
in first - line
lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS
in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo
Geoff Oxnard, an assistant professor of medicine at Dana - Farber
Cancer Institute and Harvard Medical School in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized patient last week, she's sick with metastatic lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&
Cancer Institute and Harvard Medical School
in Boston and one of Paweletz's collaborators, remarks that «I had a hospitalized
patient last week, she's sick with metastatic
lung cancer, and she's exactly the kind of patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.&
cancer, and she's exactly the kind of
patient who might have an [epithelial growth factor receptor (EGFR)-RSB- mutation, but I simply didn't have enough tissue to ask those questions yet.»
«One of the toughest challenges of
lung cancer is what to
do for
patients when the
cancer comes back
in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.
«If you look at a set of
lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hos
cancer patients, like we
did in the paper, who develop brain metastases, they all have those two genes
in their primary
lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hos
cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and
Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hos
Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.
It doesn't kill the cell that it hides
in, but is dangerous enough that it can cause infections
in individuals with an impaired immune system, such as
patients who are receiving
cancer treatment, who have pre-existing
lung problems or whose immune systems are otherwise compromised.
Clinical responses
in lung cancer patients have been impressive, with responses
in patients with advance disease whose
cancers did not respond to other treatment approaches.
I have seen many more cases of
lung cancer among nonsmokers than smokers
in the thousands of
patients I have cared for over the past thirty years, but that doesn't negate the studies
done on the subject that show only about 15 % of
lung cancer cases occur
in nonsmokers.